Parners4Access will present three thought provoking posters at ISPOR Europe 2024

LONDON - Nov. 18, 2024 - PRLog -- P4A will present three thought provoking posters at ISPOR Europe 2024 in Barcelona. With these posters, P4A showcases its commitment to advancing health economics and outcomes research (HEOR) in orphan drugs and ATMPs.

Marco is the author of a poster investigating the concept of durability (long-term duration of effect) and commented:

"At Partners4Access (P4A) we pride ourselves in our comprehensive and high-quality primary research insights. Our research and poster is aimed to answer this question, and uncover supportive evidence types likely to be impactful during payer assessments."

Samantha Morrison is presenting a poster written by Partners4Access' Digital Lead, Darren Callahan, about DMD treatment landscape, how it is evolving and the critical need for stakeholders to understand and assess these developments using a social listening. RarePULSE® (https://partners4access.com/services/digital-solutions/rarepulse/) (Partners4Access' omnichannel service) utilizes advanced analytics to deliver precise, actionable insights into patient and stakeholder experiences, allowing our customers to make data-driven decisions that improve outcomes. By spotlighting the lived experiences and concerns of those affected by DMD, we aim to provide a holistic view of the treatment landscape.

Samantha is looking forward to presenting the poster and ready to experience ISPOR: "I'm looking forward to giving a voice to rare diseases in JCA session and the discussion surrounding if there will be an impact of Medicare price negotiation on Europe."

The third poster written is by Johann Sanseau, Senior Analyst. Johann's poster focuses on one-time gene therapies and their varying success convincing cost-effectiveness (CE)-focused markets of their long-term durability. Additionally, the poster investigates CE markets that have lacked a consistent approach to the assumptions made around durability within economic models. The poster aims to determine how durability is assumed for previously assessed gene therapies to allow manufacturers to understand what are the key types of evidence that will support long-term durability claims in CE markets.

About Partners4Access

Partners4Access (P4A) is a global consultancy specializing in market access for orphan drugs, gene therapies, and other rare disease treatments. P4A's expertise lies in navigating the unique challenges of launching and accessing innovative therapies, helping clients bring life-saving treatments to patients around the world. With a team of experienced professionals, P4A provides tailored solutions to optimize pricing, reimbursement, and market access strategies

Contact:
Owen Bryant
Creative Director
obryant@partners4access.com